CastleKnight Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

CastleKnight Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.25M	Hold	11,900	–	–	0.04%	268
2025 Q4	$2.02M	Sell	11,900 -2,800	-19%	-$429K	0.04%	192
2025 Q3	$1.94M	Buy	14,700 +4,400	+43%	+$528K	0.04%	239
2025 Q2	$1.09M	Buy	+10,300	New	+$1.12M	0.03%	286

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CastleKnight Management's JAZZ Position: Q1 2026 in Review

CastleKnight Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 11,900 shares worth $2.25M. The position accounts for 0.04% of the portfolio, ranked #268.

CastleKnight Management first reported a position in JAZZ in Q2 2025 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

CastleKnight Management held 11,900 shares of Jazz Pharmaceuticals worth $2.25M as of Q1 2026.
CastleKnight Management left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
Jazz Pharmaceuticals made up 0.04% of CastleKnight Management's portfolio in Q1 2026, its #268 holding.
CastleKnight Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on CastleKnight Management's 13F filing for Q1 2026, filed 15 May 2026.